In short
Clinical trials are studying Rosuvastatin in people with different heart, stroke, and cholesterol-related conditions. These studies look at how well it works, how safe it is, and what results it can help achieve in specific patient groups, including older adults, children with inherited high cholesterol, and people at high cardiovascular risk.
Key points
- Clinical trials of Rosuvastatin are studying people with cholesterol problems, heart and blood vessel disease, stroke-related conditions, and inherited high cholesterol. Most of the studies are Phase 3 trials, with one Phase 1 bioequivalence study and one Phase 4 imaging study. The trials look at outcomes such as LDL cholesterol lowering, major cardiovascular events, bleeding risk, plaque changes in the arteries, and quality of life. Some studies compare Rosuvastatin with other statins, combination treatments, placebo, or newer lipid-lowering medicines. The target groups include adults at high cardiovascular risk, frail older adults, children with familial hypercholesterolemia, healthy volunteers, and people with recent stroke or covert brain infarction.
Overview of Rosuvastatin trials
The trial data show Rosuvastatin being studied in many different settings, mostly for people with high cardiovascular risk or cholesterol-related disease.
Most studies are Phase 3 trials, which usually means they are testing how well a treatment works in larger groups of patients.
There is also a small Phase 1 bioequivalence study in healthy volunteers and a Phase 4 imaging study in people with coronary artery disease and stable chest pain.
Conditions being studied
Rosuvastatin is being tested in people with covert brain infarction, dyslipidaemia, hyperlipidemia, hypercholesterolemia, and atherosclerotic cardiovascular disease.
Some trials focus on people after ischemic stroke or transient ischemic attack, while others study people with coronary artery disease, stable chest pain, or non-obstructive coronary artery disease.
One study includes children with heterozygous familial hypercholesterolemia, which is an inherited form of high cholesterol.
Another study looks at people with a high polygenic risk for coronary artery disease, meaning their risk is linked to many small genetic factors.
Trial design, phases, and who can join
The studies are interventional, which means participants receive a treatment and the researchers measure the results.
Several trials are pragmatic or comparative studies, meaning they are designed to test treatment choices in real clinical practice or against another active treatment.
Some studies include older adults, such as frail people aged 70 and above with recent ischemic stroke or TIA.
Other studies include healthy volunteers, adults with high cholesterol, or children with familial hypercholesterolemia.
Main outcomes and endpoints
Many Rosuvastatin trials measure LDL-C, which is the main form of bad cholesterol and a common treatment goal.
Other studies measure serious clinical events, such as MACE, MACCE, cardiovascular death, stroke, heart attack, or revascularization, which means a procedure to open blocked blood vessels.
Some trials focus on safety, including fatal or major bleeding, or on muscle-related side effects detected through symptoms and blood tests.
Other endpoints include plaque volume in the coronary arteries, health-related quality of life, hormone levels, and bioequivalence measures such as AUC and Cmax, which describe how much medicine enters the body and the highest level reached in blood.
What Rosuvastatin is compared with
Several trials compare Rosuvastatin-based treatment with other statins such as atorvastatin, pravastatin, fluvastatin, simvastatin, or combination therapy with ezetimibe or fenofibrate.
Some studies also compare Rosuvastatin treatment with placebo, especially when the main question is whether adding another medicine changes cholesterol levels or artery plaque progression.
In a few trials, Rosuvastatin is part of a larger treatment plan alongside newer lipid-lowering medicines such as inclisiran or alirocumab.
Notable trial examples
The covert brain infarction trial is a large Phase 3 study with 1202 participants, looking at whether antiplatelet and/or statin treatment adds long-term benefit for reducing vascular events and death, while also checking the risk of major bleeding.
The LEASH study compares high-intensity Rosuvastatin or Rosuvastatin/ezetimibe with the goal of helping high and very high risk patients reach LDL-C targets after 12 weeks.
The PICOLO-FH trial studies children with heterozygous familial hypercholesterolemia and measures whether treatment strategies can help them reach LDL-C below 100 mg/dL after 104 weeks.
The V-PLAQUE study uses coronary CT imaging to see whether adding inclisiran on top of statin therapy can reduce total coronary atheroma volume over 24 months in people with non-obstructive coronary artery disease.
The bioequivalence study in healthy volunteers compares two rosuvastatin/ezetimibe formulations and measures blood exposure levels to show that the test product performs like the reference product.
What these studies mean for patients
These trials show that Rosuvastatin is being studied across a wide range of patient groups, from people with inherited high cholesterol to older adults after stroke and people with known heart disease.
The main research questions are whether Rosuvastatin-based treatment can lower LDL-C, prevent serious heart and brain events, and improve overall outcomes in daily life.
Because the studies use different designs and comparison groups, they help researchers understand where Rosuvastatin fits best in prevention and treatment plans for cardiovascular disease.